Natixis Advisors LLC Acquires 4,390 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Natixis Advisors LLC increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 10.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,713 shares of the medical research company's stock after purchasing an additional 4,390 shares during the quarter. Natixis Advisors LLC owned 0.16% of Bio-Rad Laboratories worth $15,017,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Victory Capital Management Inc. lifted its position in shares of Bio-Rad Laboratories by 0.9% during the 3rd quarter. Victory Capital Management Inc. now owns 21,294 shares of the medical research company's stock valued at $7,125,000 after acquiring an additional 186 shares during the last quarter. KBC Group NV raised its position in shares of Bio-Rad Laboratories by 82.6% during the third quarter. KBC Group NV now owns 3,095 shares of the medical research company's stock worth $1,036,000 after purchasing an additional 1,400 shares during the period. OneDigital Investment Advisors LLC purchased a new stake in shares of Bio-Rad Laboratories during the third quarter valued at $220,000. Mutual of America Capital Management LLC boosted its position in shares of Bio-Rad Laboratories by 302.5% in the 3rd quarter. Mutual of America Capital Management LLC now owns 10,348 shares of the medical research company's stock valued at $3,462,000 after purchasing an additional 7,777 shares during the period. Finally, Thrivent Financial for Lutherans increased its stake in Bio-Rad Laboratories by 446.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 4,498 shares of the medical research company's stock worth $1,505,000 after purchasing an additional 3,675 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Bio-Rad Laboratories Stock Up 0.8 %

Shares of NYSE BIO traded up $1.95 during mid-day trading on Friday, reaching $256.42. The company had a trading volume of 1,439,995 shares, compared to its average volume of 289,974. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The company has a market capitalization of $7.18 billion, a price-to-earnings ratio of -3.94 and a beta of 0.98. The stock has a fifty day moving average of $303.23 and a two-hundred day moving average of $325.34. Bio-Rad Laboratories, Inc. has a 12-month low of $244.00 and a 12-month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BIO shares. Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Finally, StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.